Testing the Impact of Pre-visit Priming for Medications
2 other identifiers
interventional
1,700
0 countries
N/A
Brief Summary
We will use EHR data to identify eligible patients at BWH primary care clinics. Patients will be eligible if they have an upcoming primary care provider (PCP) appointment at an included BWH clinic, are ≥65 years, and are eligible for a medication target; exclusion criteria will include relevant EHR-documented allergies. After sharing patients with PCPs for potential opt-out, patients will be randomized 1:1 in REDCap® to intervention or usual care (no prompt). The intervention will include a pre-visit patient-facing prompt with information about the evidence-based medication target. If patients are eligible for multiple targets, one will be randomly selected. The primary clinical outcome will be measured on the day of the PCP visit using EHR data, depending on target: a) discontinuation or tapering order, or b) prescribing. Secondary outcomes will include a) these same measures in a 60-day follow-up period after the visit to capture any follow-up actions. We will use an intention-to-treat approach including patients regardless of whether the visit occurred. We plan to conduct the trial until 1700 patients are reached. We will also conduct exploratory mediation analyses of mechanisms through brief patient surveys with behavioral scales and PCP survey.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started May 2026
Shorter than P25 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 11, 2025
CompletedFirst Posted
Study publicly available on registry
December 15, 2025
CompletedStudy Start
First participant enrolled
May 15, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
September 15, 2026
Study Completion
Last participant's last visit for all outcomes
November 14, 2026
March 30, 2026
January 1, 2026
4 months
December 11, 2025
March 25, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Completion of medication prescribing/deprescribing target on day of PCP visit
The primary clinical outcome will be measured on the day of the primary care provider (PCP) visit through EHR data, depending on medication target: a) discontinuation or taper, or b) statin prescribing.
1 day
Secondary Outcomes (1)
Completion of medication prescribing/deprescribing target within 60 days
60 days
Study Arms (2)
Pre-visit patient prompts
EXPERIMENTALThe intervention itself is a pre-visit prompt delivered prior to upcoming visits that includes a brief recommendation to the patient to discuss the medication use target with the PCP at the visit and a handout about the medication.
Usual Care
NO INTERVENTIONNo intervention delivery outside of regular clinical practice.
Interventions
The intervention itself is a pre-visit prompt delivered prior to upcoming visits that includes a brief recommendation to the patient to discuss the medication use target with the PCP at the visit and a handout about the medication. The medication targets include potentially-inappropriate medications and statin prescribing.
Eligibility Criteria
You may qualify if:
- ≥65 years of age
- Have an upcoming clinic appointment with a BWH PCP at one of the included clinics
- In addition, they must meet the following eligibility criteria for at least one medication target behavior (based on EHR data):
- Statin use for primary prevention (65-75 years of age): Having a EHR diagnosis or problem list documentation of: diabetes, hypertension, smoking, or high cholesterol and estimated eligible cardiovascular risk and no current outpatient prescription for a statin
- High-risk medication use (≥65 years of age): Have an active outpatient prescription for ≥1 medication on the American Geriatrics Society Beers Criteria® List for Avoid Medications based on EHR records
You may not qualify if:
- Documented allergy to one of the components (statin).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Brigham and Women's Hospitallead
- National Institute on Aging (NIA)collaborator
- University of Southern Californiacollaborator
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
December 11, 2025
First Posted
December 15, 2025
Study Start (Estimated)
May 15, 2026
Primary Completion (Estimated)
September 15, 2026
Study Completion (Estimated)
November 14, 2026
Last Updated
March 30, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ANALYTIC CODE
- Time Frame
- These data will be available upon request. To the extent the context of data collection can be revealed without compromising privacy and identity of research participants, it will be included. Algorithms and other programming code used to identify patients for the study and evaluate study outcomes will be available upon request. We will also provide the underlying logic to build the tools to other health systems upon request.
- Access Criteria
- Data will be controlled access with the General Research Use Data Use Limitation, as allowed by the informed consent and the institutional certification, anticipated through the Aging Research Biobank.
The project will result in a Limited Data Set and a de-identified data set of the outcomes, intervention arms, and sociodemographic and clinical characteristics.